Practical Use of Decision Aids in Primary Care. Michael Soung, MD, FACP Virginia Mason Medical Center General Internal Medicine
|
|
- Elijah Garrett
- 5 years ago
- Views:
Transcription
1 Practical Use of Decision Aids in Primary Care Michael Soung, MD, FACP Virginia Mason Medical Center General Internal Medicine
2 Question #1 40 yo man with total cholesterol 170, HDL 50, LDL 90. African American, smokes 1/2 PPD, HTN on 2 meds but often forgets to take his pills. BP 160/ year ASCVD risk is 12.5%. Which of the following would NOT be an appropriate next step? A) Recommend a moderate-intensity statin B) Recommend diet / activity changes C) Explore barriers to medication adherence D) Assess motivation & confidence to quit smoking E) They are all appropriate
3 Decisions in Primary Care Shared decision making and Decision aids ACC/AHA CV risk calculator Lots of Mayo decision aids Statin Osteoporosis Depression medications Diabetes medications Some Virginia Mason examples Others as time allows
4 Shared Decision Making (SDM) 3 key elements: 1) Choice: Be clear that a decision is required 2) Options: Understand the best available evidence re: risks and benefits of each option 3) Decision: Make a decision based patient s values and preferences, with provider s guidance Health Affairs 2013;32: J Gen Intern Med 2012;27:1361-7
5 Why SDM? May improve well-being through Helping to get the right treatment for this person Better adherence to treatment Fewer concerns about illness Higher satisfaction with health outcomes 71% of patients expressed a wish to actively participate in treatment decisions And, it s just the right thing to do Autonomy, Beneficence, Non-maleficence, Justice Circ Cardiovasc Qual Outcomes. 2014;7: Circ Cardiovasc Qual Outcomes. 2014;7: BMJ 2013;346:f4147 BMJ 2012;344:e256
6 SDM Challenges Innumeracy Variable interpretations of verbal qualifiers (e.g. what is high risk?) 22% couldn t identify which was highest risk: 1 in 10, 1 in 100, or 1 in % of college-educated adults couldn t identify which is highest: 1%, 5%, 10% Many health professionals lack facility and confidence w/ numbers Circ Cardiovasc Qual Outcomes. 2014;7: Health Affairs 2013;32: Circ Cardiovasc Qual Outcomes. 2014;7: Acad Med 2010;85:
7 SDM expert recommendations Present information using Absolute Risk Risk seems larger when using relative risk Medical treatments are viewed more favorably using relative risk Highlight incremental risks distinctly from baseline risks Use pictographs patients better comprehend risk (regardless of numeracy) Circ Cardiovasc Qual Outcomes. 2014;7:
8 What s a Decision Aid? Tool to aid (shared) decision making Online, print, video, others Should include: Decision to be made Options available Outcomes (benefits, harms, uncertainties) of these options based on current evidence Help for people to think through their values and preferences BMJ 2013;346:f4147
9 Use of decisions aids improves: Knowledge of options, benefits, and harms Clarity regarding own values Informed values-based choices Patient involvement in decision making Patient-practitioner communication Use of global CV risk information: Improves accuracy of risk perception Increases statin Rx s in mod-high risk patients May reduce predicted CV risk over time Cochrane Database of Syst Rev 2014, Issue 1 BMC Health Services Research 2008;8:60-73 Arch Int Med 2010;170:230-9
10 (search ACC AHA risk calculator )
11 Question #2 55 yo man with total cholesterol 220, HDL 40, TGs 150, LDL 150. Caucasian, no significant past medical history, no family history of vascular disease or smoking. His BP is 130/75. His 10-year ASCVD risk is 7.8% What is the most appropriate next step? A) Recommend a statin B) Recommend intensive lifestyle changes C) A and B D) Recheck lipids in 3 months E) Engage in a shared decision making process
12 (search Mayo statin decision aid )
13 Question #3 79 yo caucasian woman with DXA T-score of left femoral neck of cm, 83 kg (BMI 30). No personal or family history of fragility fractures. No smoking. 1 drink of EtOH per evening. FRAX: 10 year risk of hip fracture = 3.4%. 10 year risk of major osteoporotic fracture = 13% What is the most appropriate next step? A) Recommend appropriate calcium and vitamin D B) Recommend regular weight-bearing exercise C) Recommend a bisphosphonate D) Recheck bone density in 2 years E) Engage in a shared decision making process
14 Treatment of osteoporosis 2013 National Osteoporosis Foundation: Postmenopausal women and med age 50+ with: A hip or vertebral fracture T-score < 2.5 at the femoral neck or spine T-score between -1.0 and -2.5 at the femoral neck, PLUS 10-year probability of hip fracture 3%, OR 10- year probability of major osteoporotic fracture 20% Based in part on US-specific cost-effectiveness analysis (i.e. $60,000 per QALY gained) National Osteoporosis Foundation 2013: Clinician's guide to prevention and treatment of osteoporosis Osteoporos Int 2008;19:
15 (search Mayo osteoporosis decision aid )
16 The NY Times has noticed t/can-this-treatment-help-me-theres-astatistic-for-that.html?emc=eta1 t/how-to-measure-a-medical-treatmentspotential-for-harm.html?emc=eta1
17 Clinical Scenario #4 27 yo woman with 6 months of: Depression and anhedonia, no suicidality Insomnia Poor appetite, thin at baseline Has tried other measures and is now interested in starting an antidepressant. No personal or FH antidepressant use
18 (Just search Mayo Depression Decision Aid )
19 Clinical Scenario #5 67 yo man with type 2 DM on max dose metformin Last 2 HbA1c s have both been ~8.5% Has been very adherent to healthy lifestyle He d prefer: Simplest oral regimen Lower cost Weight neutral
20 (Search Mayo diabetes decision aid )
21 Clinical Scenario #6 62 yo man, new to your clinic, scheduled for a preventive health visit. You re running about 15 minutes behind Any reading material you d like him to have while he s waiting for you?
22 VM PSA screening Decision Aid 2014 Virginia Mason Medical Center
23 VM PSA screening Decision Aid 2014 Virginia Mason Medical Center
24 Results: p<0.05 p=0.01 p= Virginia Mason Medical Center
25 VM Mammogram Decision Aid 2014 Virginia Mason Medical Center
26 VM Mammogram Decision Aid 2014 Virginia Mason Medical Center
27 JAMA 2014;312:2585
28 Clinical scenario #7 72yo woman asks about Chest CT to screen for lung cancer. Currently smoking Smoked 1 PPD for 45 years No asbestos exposure
29 (search Lung cancer screening decision tool )
30 (search Lung cancer screening decision tool )
31
32
33 Take home points Shared decision making = right thing to do And it doesn t have to take forever Be clear that a decision is needed And that your patient is the decider Our job is to help diagnose values and preferences as much as it is to diagnose diseases Consider using decision aids to improve communication and decision quality
Understanding new international guidelines to tackle CV Risk: A practical model John Deanfield, MD UCL, London United Kingdom s
Understanding new international guidelines to tackle CV Risk: A practical model John Deanfield, MD UCL, London United Kingdom s Ho Chi Minh City, Vietnam August 7, 2014 JBS 2 Risk Guidelines (2005) Based
More informationOsteoporosis: A Tale of 3 Task Forces!
Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker
More informationWho cares about fractures! is more important. October 3, 2014 CSIM Workshop Brian Wirzba, MD, FRCPC, FACP Clinical Professor Grey Nuns Hospital
Isn t Osteoporosis just a T Score less than 2.5?? Who cares about fractures! is more important. Why do I need to know this? October 3, 2014 CSIM Workshop Brian Wirzba, MD, FRCPC, FACP Clinical Professor
More informationModule 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC
Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment William D. Leslie, MD MSc FRCPC Case #1 Age 53: 3 years post-menopause Has always enjoyed excellent health with
More informationCASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationUsing the FRAX Tool. Osteoporosis Definition
How long will your bones remain standing? Using the FRAX Tool Gary Salzman M.D. Director Banner Good Samaritan/ Hayden VAMC Internal Medicine Geriatric Fellowship Program Phoenix, Arizona Using the FRAX
More informationOsteoporosis: A Tale of 3 Task Forces!
Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker
More informationOsteoporosis Treatment Overview. Colton Larson RFUMS October 26, 2018
Osteoporosis Treatment Overview Colton Larson RFUMS October 26, 2018 Burden of Disease Most common bone disease 9.9 million Americans + 43.1 million Americans have low bone mineral density (BMD) Stealthy
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationDisclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?
Disclosures No relationships (not even to an employer) No off-label uses Cholesterol Lowering Guidelines: What now?, FACP 1 2 65-year-old white woman Total cholesterol 175mg/dL HDL 54 mg/dl LDL 96 mg/dl
More informationBeyond the T-score: New Thinking in Osteoporosis 2
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/beyond-the-t-score-new-thinking-in-osteoporosis-
More informationOsteoporosis: An Overview. Carolyn J. Crandall, MD, MS
Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Objectives Review osteoporosis
More informationPlacebo-Controlled Statin Trials
PREVENTION OF CHD WITH LIPID MANAGEMENT AND ASPIRIN: MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of
More informationCoordinator of Post Professional Programs Texas Woman's University 1
OSTEOPOROSIS Update 2007-2008 April 26, 2008 How much of our BMD is under our control (vs. genetics)? 1 2 Genetic effects on bone loss: longitudinal twin study (Makovey, 2007) Peak BMD is under genetic
More informationDisclosures. Overview 9/30/ ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults 2014 AAHP Fall Seminar Sherry Myatt, PharmD, BCPS Assistant Director of Pharmacy for
More informationCalculating Risk for Primary Prevention of Cardiovascular Disease (CVD)
Calculating Risk for Primary Prevention of Cardiovascular Disease (CVD) 2. Welcome by Stacey Sheridan, MD, MPH Hello. My name is Stacey Sheridan, and I m here as your partner in Heart Health Now. The North
More informationThe who, what, why, where, and when of Clinical Practice Guidelines (CPGs)
The who, what, why, where, and when of Clinical Practice Guidelines (CPGs) Appraisal of Guidelines for Research and Evaluation (AGREE) II DOMAIN 1. SCOPE AND PURPOSE DOMAIN 2. STAKEHOLDER INVOLVEMENT DOMAIN
More informationNorthwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient?
Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient? Donald M. Lloyd-Jones, MD, ScM, FACC, FAHA Senior Associate Dean Chair, Department of Preventive
More informationCase Presentation. Moderator: Sharon Liu, DO Associate Internal Medicine Chief Austin Regional Clinic Austin, Texas
Case Presentation Moderator: Sharon Liu, DO Associate Internal Medicine Chief Austin Regional Clinic Austin, Texas Izzy (2006) 51 y/o Hispanic woman with a history of diabetes and obesity. Her diabetes
More informationMisperceptions still exist that cardiovascular disease is not a real problem for women.
Management of Cardiovascular Risk Factors in the Cynthia A., MD University of California, San Diego ARHP 9/19/08 Disclosures Research support Wyeth, Lilly, Organon, Novo Nordisk, Pfizer Consultant fees
More informationManagement of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
More informationLipid Management 2013 Statin Benefit Groups
Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationBest Practices in Cardiac Care: Getting with the Guidelines
Best Practices in Cardiac Care: Getting with the Guidelines December 9, 2014 Agenda Cardiovascular Disease: How do the guidelines fit into an implementation scheme? What the guidelines set out to accomplish
More informationHealth Outcome Prioritization as a Tool for Decision Making Among Older Persons With Multiple Chronic Conditions
Health Outcome Prioritization as a Tool for Decision Making Among Older Persons With Multiple Chronic Conditions Mary Tinetti, M.D. Canadian Geriatrics Society May, 2013 CFPC CoI Templates: Slide 1 Faculty/Presenter
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationTalking to patients with osteoporosis about initiating therapy
Talking to patients with osteoporosis about initiating therapy Deborah Sellmeyer, MD Director, Johns Hopkins Metabolic Bone Center Dept of Medicine, Division of Endocrinology Disclosure DSMB member for
More informationPrimary Prevention of Cardiovascular Disease (CVD) Events with Statins. 1 Primary Prevention of Cardiovascular Disease (CVD) Events with Statins
Primary Prevention of Cardiovascular Disease (CVD) Events with Statins 1 Primary Prevention of Cardiovascular Disease (CVD) Events with Statins 2 Welcome by Michael Pignone, MD, MPH Hi, my name is Dr.
More informationBone density scanning and osteoporosis
Bone density scanning and osteoporosis What is osteoporosis? Osteoporosis occurs when the struts which make up the mesh-like structure within bones become thin causing them to become fragile and break
More informationPatient-centered Translation of Evidence Into Practice
Patient-centered Translation of Evidence Into Practice Nilay Shah Division of Health Care Policy and Research Center for the Science of Health Care Delivery Mayo Clinic Disclosures Funding provided by:
More informationOsteoporosis challenges
Osteoporosis challenges Osteoporosis challenges Who should have a fracture risk assessment? Who to treat? Drugs, holidays and unusual adverse effects Fracture liaison service? The size of the problem 1
More informationAdvanced medicine conference. Monday 20 Tuesday 21 June 2016
Advanced medicine conference Monday 20 Tuesday 21 June 2016 Osteoporosis: recent advances in risk assessment and management Juliet Compston Emeritus Professor of Bone Medicine Cambridge Biomedical Campus
More informationInformed Consent, Goals and Targets
Informed Consent, Goals and Targets Kenneth Brummel-Smith, MD Charlotte Edwards Maguire Professor of Geriatrics Florida State University College of Medicine Objectives Understand the nature of true informed
More informationShared Decision Making and Minimally Disruptive Medicine
Shared Decision Making and Minimally Disruptive Medicine Ian Hargraves JP Brito KER UNIT Center for Clinical and Translational Sciences Mayo Clinic Minimally Disruptive Medicine Effective Care that Fits
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationShared Decision Making in Diabetes: What, Why, and How? Nilay D. Shah Mayo Clinic Rochester, Minnesota, USA
Shared Decision Making in Diabetes: What, Why, and How? Nilay D. Shah Mayo Clinic Rochester, Minnesota, USA Disclosures Funding provided by: AHRQ: R18 HS019214; R18 HS018339 NIDDK: R34 DK84009 Foundation
More informationChanges to the Guideline: update to mammogram screening ages (possible benefit to screen in age if high risk)
Adult Preventive Clinical Guideline (21 & over) Line of Business: DE Medicaid Summary: The Adult Preventive Clinical Guideline is meant to provide guidance for preventive care for the general, adult population.
More informationPlacebo-Controlled Statin Trials Prevention Of CVD in Women"
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationLipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice
Lipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice Vera Bittner, MD, MSPH Professor of Medicine Section Head, Preventive Cardiology Medical Director, Cardiac Rehabilitation
More informationCurrent Issues in Osteoporosis
Current Issues in Osteoporosis California AACE 18TH Annual Meeting & Symposium Marina del Rey, CA September 15, 2018 Michael R. McClung, MD, FACP,FACE Director, Oregon Osteoporosis Center Portland, Oregon,
More informationNEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT
NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF OSTEOPOROSIS: OVERVIEW Definitions Risk factors
More informationPrevention: When Do Benefits Start and End? What Do They Have in Common?
Prevention: When Do Benefits Start and End? Providence Internal Medicine Spring Symposium April 14, 2016 Mari Kai, MD What Do They Have in Common? 82 year old female 62 year old male Estimated Life Expectancy
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationPage 1. New Developments in Osteoporosis. What s New in Osteoporosis
New Developments in Osteoporosis Eliseo J. Pérez-Stable MD Professor of Medicine Division of General Internal Medicine Department of Medicine July 4, 2013 Declaration of full disclosure: No conflict of
More informationWhen Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes
When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes Kim K. Birtcher, MS, PharmD, AACC, FNLA, CLS, BCPS (AQ-Cardiology), CDE Clinical Professor University of Houston College
More informationUpdates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationManagement of postmenopausal osteoporosis
Management of postmenopausal osteoporosis Yeap SS, Hew FL, Chan SP, on behalf of the Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis,
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationWhat Is FRAX & How Can I Use It?
What Is FRAX & How Can I Use It? Jacqueline Osborne PT, DPT Board Certified Geriatric Clinical Specialist Certified Exercise Expert for the Aging Adult Brooks Rehabilitation; Jacksonville, FL Florida Physical
More information15 min: Large group presentation: The divide between guideline-based care and patient preferences: examples from current guidelines Michael
Society of General Internal Medicine Annual Meeting 2015 Evidence-Based Practice Guidelines and Shared Decision Making: Conflicting or Complementary Strategies for Doing the Right Thing in Health Care?
More informationLearning Objectives. Controversies in Osteoporosis Prevention and Management. Definition. Presenter Disclosure Information.
4 4:45 pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS: WHERE DO WE STAND WITH THE NEW PRACTICE GUIDELINES? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant financial relationships
More informationOVERVIEW WOMEN S HEALTH: YEAR IN REVIEW
OVERVIEW WOMEN S HEALTH: YEAR IN REVIEW Judith Walsh, MD, MPH Professor of Medicine UCSF Update in Women s Health for SGIM Drs. Mary Beattie and Pam Charney Review of literature from March, 2008 through
More informationInterdependence of Evidence-based Practice & Shared Decision Making Implications for Quality
New York Academy of Medicine August 6, 2015 Interdependence of Evidence-based Practice & Shared Decision Making Implications for Quality Henry H. Ting, MD, MBA Senior Vice President & Chief Quality Officer,
More informationThe Glasgow UK Experiment: What a Working System Can Deliver
ASBMR Symposium Systems Approaches to Secondary Fracture Prevention: Doing Something that Actually Works The Glasgow UK Experiment: What a Working System Can Deliver Alastair R. McLellan MD, FRCP Western
More informationCOPD-Related Musculoskeletal Disease. Jessica Bon Field, MD, MS 2017 Update in Internal Medicine October 20, 2017
COPD-Related Musculoskeletal Disease Jessica Bon Field, MD, MS 2017 Update in Internal Medicine October 20, 2017 A 60-year old man with COPD comes into your office for a routine office visit. He is a former
More informationLearning Objectives. Controversies in Osteoporosis Prevention and Management. Etiology. Presenter Disclosure Information. Epidemiology.
12:45 1:30pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn
More informationOsteoporosis Clinical Guideline. Rheumatology January 2017
Osteoporosis Clinical Guideline Rheumatology January 2017 Introduction Osteoporosis is a condition of low bone mass leading to an increased risk of low trauma fractures. The prevalence of osteoporosis
More informationUnderstanding NICE guidance. NICE technology appraisal guidance advises on when and how drugs and other treatments should be used in the NHS.
Understanding NICE guidance Information for people who use NHS services Alendronate, etidronate, risedronate, strontium ranelate and raloxifene for preventing bone fractures in postmenopausal women with
More informationConflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines
Conflict of Interest Disclosure Updates for the Ambulatory Care Pharmacist: Dyslipidemia and CV Risk Assessment No conflicts of interest to disclose 2014 Updates to the Updates in Ambulatory Care Pharmacy
More informationManaging Dyslipidemia and ASCVD Risk: Confusion, Controversy Consensus
Managing Dyslipidemia and ASCVD Risk: Confusion, Controversy Consensus Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA Chair, ACC Prevention of Cardiovascular Disease Council and Section The Medical University
More informationPrevention Strategies: Wisdom and Folly
Prevention Strategies: Wisdom and Folly Victoria Maizes MD Executive Director Arizona Center for Integrative Medicine Professor of Medicine, Family Medicine and Public Health University of Arizona \ What
More informationOfficial Positions on FRAX
196 96 DEPLIANT 3,5x8,5.indd 1 2010 Official Positions on FRAX 21.03.11 11:45 Interpretation and Use of FRAX in Clinical Practice from the International Society for Clinical Densitometry and International
More informationCoronary Heart Disease in Women Go Red for Women
Coronary Heart Disease in Women Go Red for Women Dr Fiona Stewart Green Lane Cardiovascular Service and National Women s Health Auckland City Hospital Auckland Heart Group Women are Different from Men
More informationControversies in Osteoporosis Management
Controversies in Osteoporosis Management 2018 Northwest Rheumatism Society Meeting Portland, OR April 28, 2018 Michael R. McClung, MD, FACP Director, Oregon Osteoporosis Center Portland, Oregon, USA Institute
More informationSummary. Background. Diagnosis
March 2009 Management of post-menopausal osteoporosis This bulletin focuses on the pharmacological management of patients with post-menopausal osteoporosis both those with clinically evident disease (e.g.
More informationDisclosures. Diagnostic Challenges in Osteoporosis: Whom To Treat 9/25/2014
Disclosures Diagnostic Challenges in Osteoporosis: Whom To Treat Ethel S. Siris, MD Columbia University Medical Center New York, NY Consultant on scientific issues for: AgNovos Amgen Eli Lilly Merck Novartis
More informationOsteoporosis as a Focus for Practice Improvement
Osteoporosis as a Focus for Practice Improvement Karen E. Hansen, M.D. Assistant Professor of Medicine Rheumatology and Endocrine Sections University of Wisconsin Madison, WI Postmenopausal Osteoporosis
More informationDyslipidemia in women: Who should be treated and how?
Dyslipidemia in women: Who should be treated and how? Lale Tokgozoglu, MD, FACC, FESC Professor of Cardiology Hacettepe University Faculty of Medicine Ankara, Turkey. Cause of Death in Women: European
More informationTechnology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464
Bisphosphonates for treating osteoporosis Technology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationBlood Pressure LIMBO How Low To Go?
Blood Pressure LIMBO How Low To Go? Joseph L. Kummer, MD, FACC Bryan Heart Spring Conference April 21 st, 2018 Hypertension Epidemiology Over a billion people have hypertension Major cause of morbidity
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationImprove the Adherence, Save the Life
Improve the Adherence, Save the Life Park, Chang Gyu Korea University Guro Hospital Cardiovascular Center Seoul, Korea Modifiable CVD Risk Factors Obesity BMI Hypertension Cholesterol LDL HDL Diabetes
More information1
www.osteoporosis.ca 1 2 Overview of the Presentation Osteoporosis: An Overview Bone Basics Diagnosis of Osteoporosis Drug Therapies Risk Reduction Living with Osteoporosis 3 What is Osteoporosis? Osteoporosis:
More informationPreventing and Treating High Blood Pressure
Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure
More informationPart 1: Obesity. Dietary recommendations in Obesity, Hypertension, Hyperlipidemia, and Diabetes 10/15/2018. Objectives.
Dietary recommendations in Obesity, Hypertension, Hyperlipidemia, and Diabetes Stephen D. Sisson MD Objectives To review dietary recommendations in the following conditions: Obesity Hypertension Diabetes
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Osteoporosis- Do We Need to Think Beyond Bone Mineral Density? Dr Preeti Soni 1, Dr Shipra
More informationDownload slides:
Download slides: https://www.tinyurl.com/m67zcnn https://tinyurl.com/kazchbn OSTEOPOROSIS REVIEW AND UPDATE Boca Raton Regional Hospital Internal Medicine Conference 2017 Benjamin Wang, M.D., FRCPC Division
More informationMeta-analysis: analysis:
1 Diabetes and TZDs: Risk Factors for Fracture Ann Schwartz, PhD Dept. of Epidemiology and Biostatistics University of California San Francisco July 2010 Osteoporosis CME Presenter Disclosure Information
More informationCARDIOVASCULAR HEALTH LIVING A HEART HEALTHY LIFE. Matt Handley MD Group Health Physicians
CARDIOVASCULAR HEALTH LIVING A HEART HEALTHY LIFE Matt Handley MD Group Health Physicians WILLIE SUTTON Add together your risk of dying from breast cancer and colon cancer (women), or prostate cancer and
More informationChallenging the Current Osteoporosis Guidelines. Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA
Challenging the Current Osteoporosis Guidelines Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Whom to screen Which test How to diagnose Whom to treat Benefits
More informationMedical Apps for Cardiology Uses. There s an App for That!
Medical Apps for Cardiology Uses There s an App for That! Audience Participation Question #1 1. ASCVD Risk App What is the predicted 10 year CV event rate for a 57 y/o black male patient with treated
More informationJohn J. Wolf, DO Family Medicine
John J. Wolf, DO Family Medicine Objectives: 1. Review incidence & Risk of Osteoporosis 2.Review indications for testing 3.Review current pharmacologic & Non pharmacologic Tx options 4.Understand & Utilize
More informationModule 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension
Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More informationLipids: Translating Studies into Practice. WD04: Cortney Joneikis, MD, MS Bob Gleeson, MD Jeff Whittle, MD, MPH
Lipids: Translating Studies into Practice WD04: Cortney Joneikis, MD, MS Bob Gleeson, MD Jeff Whittle, MD, MPH Discussants: Bob Gleeson, MD Assistant Professor of Medicine, General Internal Medicine Medical
More informationLipids What s new? Meera Jain, MD Providence Portland Medical Center
Lipids 2016- What s new? Meera Jain, MD Providence Portland Medical Center 1 Can I trust the ASCVD risk calculator? Do harms outweigh benefits in primary prevention? Is there anything besides a statin?
More informationAn audit of osteoporotic patients in an Australian general practice
professional Darren Parker An audit of osteoporotic patients in an Australian general practice Background Osteoporosis is a major contributor to morbidity and mortality in Australia, and is predicted to
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationBAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008
BAD TO THE BONE Peter Jones, Rheumatologist QE Health, Rotorua GP CME Conference Rotorua, June 2008 Agenda Osteoporosis in Men Vitamin D and Calcium Long-term treatment with Bisphosphonates Pathophysiology
More informationNew 2010 Osteoporosis Guidelines: What you and your health provider need to know QUESTIONS&ANSWERS
New 2010 Osteoporosis Guidelines: What you and your health provider need to know QUESTIONS&ANSWERS Wednesday, December 1, 2010 1:00 p.m. to 2:00 p.m. ET 1. I m 55 years old. I ve been taking Fosavance
More informationE-portfolio guide. This guide will take you through, step by step, the type of information we expect you to record at each stage of your cycle.
E-portfolio guide The e-portfolio is designed to help you become a reflective learner and to emphasise the knowledge you are picking up on a daily basis. This guide will take you through, step by step,
More informationACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS
ACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS Ziyad Ghazzal MD, FACC, FSCAI Professor of Medicine Deputy Vice President/Dean Associate Dean for Clinical Affairs American University of Beirut Adjunct
More informationThe Latest Generation of Clinical
The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform
More informationEU Osteoporosis Report MALTA
EU Osteoporosis Report 2007-2008 MALTA Overview completed by: Dr Raymond Galea MD, FRCOG, Acc O&G.(Leu) Progress report completed by: Dr Raymond Galea in conjunction with the Strategy and Sustainability
More informationScreening Guidelines: Women
The Situation 1 in 2 postmenopausal women and 1 in 5 older men will have an osteoporosis-related fracture in their lifetimes Osteoporosis Definition NIH Consensus Conference A skeletal disorder characterized
More informationSubmission to the National Institute for Clinical Excellence on
Submission to the National Institute for Clinical Excellence on Strontium ranelate for the prevention of osteoporotic fractures in postmenopausal women with osteoporosis by The Society for Endocrinology
More informationClinical Guideline Adult Preventive (21 & Over)
COUNSELING SCREENING Clinical Indicator Ages 21-39 Ages 40-49 Ages 50-64 Ages 65+ Assessing tobacco use Every visit Every visit Every visit Every visit Advising smokers to quit At least annually At least
More informationSupplementary on line
Supplementary on line French recommendations for CV, infection, cancer and osteoporotic fracture risks in rheumatoid arthritis.[1] Cardiovascular disease Cardiovascular risk should be assessed annually
More information